Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ajh.25310 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
High dose chemotherapy with autologous stem cell rescue in children and young adults with high-risk Ewing sarcoma: A single institute experience in Taiwan.
J Chin Med Assoc
October 2024
Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
Article Synopsis
- A study investigated the effectiveness of high-dose chemotherapy with autologous stem cell rescue (HDC-ASCR) in treating high-risk pediatric patients with Ewing sarcoma (ES), a rare cancer.
- Over 17 years, researchers analyzed 20 patients who received this treatment, focusing on their disease response, complications, and survival rates.
- Results showed promising outcomes with a 5-year overall survival rate of 54.5%, indicating HDC-ASCR could significantly benefit patients compared to traditional treatments.
Acute Erythroid Leukemia Post-Chemo-Radiotherapy and Autologous Stem Cell Transplantation Due to Multiple Myeloma: Tracing the Paths to Leukemic Transformation.
Int J Mol Sci
July 2024
Department of Pathology, Faculty of General Medicine, University of Debrecen, 4032 Debrecen, Hungary.
Article Synopsis
- * AEL is characterized by specific genetic changes, including multi-allelic mutations, and can develop after treatments like chemotherapy and stem cell transplants, as seen in two case studies.
- * Several potential mechanisms for AEL's development post-treatment are proposed, including the presence of abnormal stem cells, survival of mutated cells after chemotherapy, and new mutations arising from treatment-related complications.
High-dose chemotherapy for Ewing sarcoma and Rhabdomyosarcoma: A systematic review by the Australia and New Zealand sarcoma association clinical practice guidelines working party.
Cancer Treat Rev
March 2024
Children's Cancer Centre, The Royal Children's Hospital Melbourne, VIC 3000, Australia; Department of Paediatrics, The University of Melbourne, Parkville VIC 3052 Australia; Murdoch Children's Research Institute, Melbourne, Australia.
Article Synopsis
- Patients with serious forms of Ewing sarcoma (ES) and rhabdomyosarcoma (RMS) may benefit from a treatment called high-dose chemotherapy with stem cell transplant, but it's still unclear how much it helps and it can cause serious side effects.
- A review of many studies found that for some ES patients, this treatment can improve their chances of living longer compared to standard chemotherapy, especially if they receive it after a specific type of chemotherapy.
- However, for RMS patients and those with advanced ES, the evidence doesn't show a clear benefit, and more research is needed to understand the best treatment options.
In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT.
Bone Marrow Transplant
April 2024
Department of Stem Cell Transplantation, University College London Hospitals, London, UK.
Bortezomib (Vel)- Melphalan 200 mg/m2 (Mel200) (Vel-Mel) has been utilised to intensify conditioning in autologous hematopoietic stem cell transplantation (AHCT) for multiple myeloma (MM). This EBMT registry-based study compared Vel-Mel with Mel200 during upfront AHCT. Between 2010 and 2017, MM patients who received Vel-Mel (n = 292) conditioning were compared with 4,096 Mel200 patients in the same 58 centres.
View Article and Find Full Text PDFClinicopathologic Features of Therapy-Related Myeloid Neoplasms in Patients with Myeloma in the Era of Novel Therapies.
Mod Pathol
June 2023
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address:
Article Synopsis
- Therapy-related myeloid neoplasms (t-MN) can develop in myeloma patients treated with novel therapies, affecting predominantly older adults with a median age of 68.
- The study analyzed 66 patients, revealing that those receiving high-dose melphalan-based autologous stem cell transplantation (HDM-ASCT) in addition to other therapies had a longer time before developing t-MN compared to those receiving only HDM-ASCT.
- The most common types of t-MN were myelodysplastic syndrome, with key genetic mutations identified (like TP53), and the overall median survival post-diagnosis of t-MN was 18.4 months, indicating relatively poor outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!